2月13日晚间，美团在港交所公告，集团预期于2025年度录得亏损约人民币233亿元至人民币243亿元， 相比之下，集团于2024年度录得溢利约人民币358.08亿元。集团于2025年度的预期亏损，主要是由于核 心本地商业分部从2024年度约人民币524.15亿元的经营溢利转为2025年度约人民币68亿元至人民币70亿 元的经营亏损，同时集团进一步加大了海外业务的投入。尤其是，为了应对2025年度行业空前激烈的竞 争，集团已战略性地加大对整个生态体系的投入，以增强核心优势并推动可持续增长。 ...

Core Viewpoint - Kingworld Medicines Group (01110) expects a significant decline in profit for the first half of 2025, projecting a year-on-year decrease of approximately 70% to 75% compared to a profit of 45.6 million yuan in the first half of 2024 [1] Financial Performance - The company anticipates a loss attributable to shareholders of approximately 4.5 million yuan for the first half of 2025, while projecting a profit attributable to shareholders of about 30.7 million yuan for the first half of 2024 [1] Business Operations - The board attributes the decrease in profit primarily to a reduction in gross profit of approximately 50% to 55% from its Chinese distribution business for imported pharmaceutical and health products, which is due to a slowdown in market demand for these products [1] - This decline in gross profit is partially offset by an increase in gross profit of about 10% to 15% from Shenzhen Dongdixin Technology Co., Ltd [1]